Skip to main content
. 2019 Sep;8(5):1950–1964. doi: 10.21037/tcr.2019.09.15

Table 1. Baseline characteristics of HCC patients.

Parameters DEB-TACE group (N=171) cTACE group (N=164) P value
Age (years) 54.9±11.8 55.4±13.2 0.742
Gender (male/female) 145/26 146/18 0.252
History of drink (n/%) 46 (26.9) 37 (22.6) 0.358
History of HB (n/%) 109 (63.7) 109 (66.5) 0.606
History of HC (n/%) 6 (3.5) 3 (1.8) 0.342
History of cirrhosis (n/%) 72 (42.1) 86 (52.4) 0.058
Tumor location (n/%) 0.795
   Unilobar 118 (69.0) 111 (67.7)
   Bilobar 53 (31.0) 53 (32.3)
Tumor distribution (n/%) 0.458
   Unifocal 113 (66.1) 102 (62.2)
   Multifocal 58 (33.9) 62 (37.8)
Largest nodule size (cm) 7.9 (4.8–12.1) 6.5 (3.4–7.8) 0.004
Portal vein invasion (n/%) 53 (31.0) 38 (23.2) 0.108
Hepatic vein invasion (n/%) 26 (15.2) 22 (13.4) 0.640
ECOG performance status (n/%) 0.087
   0 50 (29.2) 59 (36.0)
   1 92 (53.8) 87 (53.0)
   2 29 (17.0) 17 (10.4)
   3 0 (0.0) 1 (0.6)
Child-Pugh stage (n/%) 0.743
   A 136 (79.5) 133 (81.1)
   B 34 (19.9) 29 (17.7)
   C 1 (0.6) 2 (1.2)
BCLC stage (n/%) 0.379
   A 36 (21.1) 40 (24.4)
   B 73 (42.7) 73 (44.5)
   C 54 (31.6) 40 (24.4)
   D 8 (4.7) 11 (6.7)
Blood routine
   WBC (×109 cell/L) 4.9 (3.9–6.5) 5.1 (3.7–6.9) 0.603
   RBC (×1012 cell/L) 4.2 (3.7–4.8) 4.3 (3.9–4.7) 0.461
   ANC (%) 48.1 (3.0–64.5) 52.7 (3.2–63.4) 0.650
   Hb (g/L) 128.0 (112.0–145.0) 132.0 (118.0–141.0) 0.544
   PLT (×109 cell/L) 143.0 (76.0–210.0) 147.5 (93.8–221.5) 0.539
Kidney function
   BCr (μmol/L) 72.5 (61.0–85.4) 73.0 (63.0–83.0) 0.696
   BUN (mmol/L) 4.7 (3.9–5.8) 4.8 (3.9–6.0) 0.398
Tumor markers
   AFP (μg/L) 203.0 (8.6–1,210.0) 82.6 (5.6–1,000.0) 0.058
   CEA (μg/L) 1.8 (1.0–2.9) 2.1 (1.2–3.2) 0.335
   CA199 (kμ/L) 21.7 (7.9–35.2) 20.1 (8.2–34.2) 0.668
Previous treatments (n/%)
   cTACE 62 (36.3) 40 (24.4) 0.018
   Surgery 22 (12.9) 31 (18.9) 0.130
   Systematic chemotherapy 3 (1.8) 3 (1.8) 0.959
   Radiofrequency ablation 7 (4.1) 7 (4.3) 0.936
   Targeted therapy 7 (4.1) 2 (1.2) 0.104

Data were presented as mean ± standard deviation, median (25th–75th quantiles) or count (%). Comparison between 2 groups was determined by t test, Wilcoxon rank sum test or Chi-square test. P value <0.05 was considered significant, and the significant results were shown in boldface. HCC, hepatocellular carcinoma; DEB-TACE, drug-eluting bead transarterial chemoembolization; cTACE, conventional transarterial chemo-embolization; HB, hepatitis b; HC, hepatitis c; ECOG, Eastern Cooperative Oncology Group; BCLC, Barcelona Clinic Liver Cancer; WBC, white blood cell; RBC, red blood cell; ANC, absolute neutrophil count; Hb, hemoglobin; PLT, platelet; BCr, blood creatinine; BUN, blood urea nitrogen; AFP, alpha fetoprotein; CEA, carcino-embryonic antigen; CA199, carbohydrate antigen 199.